Biomarkers-based personalized follow-up in chronic heart failure improves patient's outcomes and reduces care associate cost.

ABSTRACT:

Background

Heart failure (HF) is a major and growing medical and economic problem, with high prevalence and incidence rates worldwide. Cardiac Biomarker is emerging as a novel tool for improving management of patients with HF with a reduced left ventricular ejection fraction (HFrEF).

Methods

This is a before and after interventional study, that assesses the impact of a personalized follow-up procedure for HF on patient's outcomes and care associated cost, based on a clinical model of risk stratification and personalized management according to that risk. A total of 192 patients were enrolled and studied before the intervention and again after the intervention. The primary objective was the rate of readmissions, due to a HF. Secondary outcome compared the rate of ED visits an

SUBMITTER: Leon-Justel A 

PROVIDER: S-EPMC8106851 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature